Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2004; 44:1763-1771, doi:10.1016/j.jacc.2004.06.075
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maeder, M.
Right arrow Articles by Rickli, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maeder, M.
Right arrow Articles by Rickli, H.

Contrast nephropathy: Review focusing on prevention

Micha Maeder, MD*,*, Maja Klein, MD{dagger}, Thomas Fehr, MD{ddagger} and Hans Rickli, MD*

* Division of Cardiology, Department of Internal Medicine
{dagger} Division of General Internal Medicine, Department of Internal Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland
{ddagger} Transplantation Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA



View larger version (36K):

[in a new window]
 
Figure 1 Suggested algorithm for therapeutic recommendations to prevent contrast nephropathy. *Angiotensin-converting enzyme inhibitors, angiotensin receptor blocking agents, non-steroidal anti-inflammatory drugs, diuretics, aminoglycosides, calcineurin inhibitors; {dagger}chronic renal insufficiency, diabetes, multiple myeloma, congestive heart failure, or age >70 years. b.i.d. = twice a day; IV = intravenous.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement